Summary of Conference Call on HuiTai Medical Industry Overview - The conference call primarily discusses the **high-value medical consumables industry**, particularly focusing on **coronary access products** in the **European market** [1][4][6]. Key Points and Arguments - **Market Positioning**: HuiTai has established a comprehensive product line for coronary access products in Europe, which includes angiography kits, catheters, guidewires, and balloons, all of which have received CE certification and have been sold for several years [1][4]. - **Market Dynamics**: The European coronary access consumables market is dominated by **Medtronic** and **Abbott**, with **Terumo** recognized for sheaths, hydrophilic guidewires, and balloons. Chinese companies like **HuiTai** and **Bossma** are emerging in specific niches [1][6][7]. - **Growth Potential**: HuiTai aims to enhance its brand image through differentiated designs, such as extended catheters and micro-catheters, and anticipates a future growth rate of **40%-50%** [1][10]. - **Sales Strategy**: The company primarily utilizes a **distribution model** in Europe, with multiple distributors per country, and plans to refine this to a single distributor per region as the market expands [1][11]. - **Brand Recognition**: HuiTai's brand, **APP Medical**, ranks among the top four for extended catheters in Europe, although it struggles to break into the top five for more commonly used devices like balloons due to intense competition [1][13]. - **Pricing Structure**: The factory prices of coronary access products in Europe are comparable to domestic procurement prices, with fluctuations between **80% to 120%** of domestic prices [1][17]. - **Reimbursement Policies**: In Europe, reimbursement for balloon products does not differentiate by brand, and prices may vary based on procurement agreements [1][16][14]. - **Market Growth**: The growth in the European market is expected to be primarily driven by PCI consumables, with peripheral products still in the registration phase [1][23]. Additional Important Insights - **International Sales Contribution**: The largest contribution to HuiTai's overseas sales comes from the **Asia-Pacific region**, followed by **Latin America**, **Middle East and Africa**, and the least from the **CIS** [1][24]. - **OEM and ODM Operations**: HuiTai engages in both **OEM** and **ODM** businesses, primarily managed by its factory in Hunan [1][27]. - **Local Presence**: The company plans to establish local warehousing and offices in Europe to better manage operations, with a current presence in Indonesia [1][33][26]. - **Competitive Landscape**: Domestic competitors in the Asia-Pacific and Latin American regions include **Bossma**, **Shengmei**, and **Lepu**, each with unique strengths in product offerings [1][31]. - **Future Plans**: HuiTai is focused on expanding its product registration and increasing its overseas workforce, which has grown from under **30** to over **40** employees since 2023 [1][29]. This summary encapsulates the key insights from the conference call regarding HuiTai Medical's strategies, market positioning, and growth potential in the high-value medical consumables sector.

Group 1 - The government is implementing significant tax incentives to encourage the relocation of medical consumables production from abroad to domestic markets, particularly in Hangzhou, to make these products more accessible and affordable for local patients [1] - 泰尔茂医疗产品 (Hangzhou) Co., Ltd. has received a registration certificate for its "guide wire" product from the Zhejiang Provincial Drug Administration, marking a significant step in the localization of imported medical consumables in Hangzhou [1] - A new tax policy announced by the Ministry of Finance, State Administration of Taxation, and Ministry of Commerce allows eligible foreign investors to offset 10% of their investment amount against their taxable income from January 1, 2025, to December 31, 2028 [1] Group 2 - The "Tax Road Pass·In Zhejiang" international tax service brand has been established to reduce tax burdens and enhance service efficiency, having provided one-on-one project management for 146 key foreign investment projects [2] - The tax authorities in Hangzhou have created a multilingual tax consultation service, offering support in 14 languages, which helps foreign enterprises navigate policies and reduce compliance risks [2] - In 2024, Hangzhou achieved an actual foreign investment utilization of $6.542 billion, ranking third among all cities in China, following Shanghai and Beijing [2]

创业板投资风险提示 本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业 融合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高 等特点，投资者面临较大的市场风险。投资者应充分了解创业板的投资风险 及本公司所披露的风险因素，审慎作出投资决定。 国科恒泰（北京）医疗科技股份有限公司 （北京市北京经济技术开发区经海四路 25 号 6 号楼 5 层 501C 室） 首次公开发行股票并在创业板上市 招股说明书 保荐人（主承销商） （深圳市福田区福田街道金田路 2026 号能源大厦南塔楼 10-19 层） 招股说明书 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 招股说明书 ...